tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

PTGX Stock Latest News

Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)
TipRanks NewswireEntera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)
12d ago
AZN
IBO
Protagonist Therapeutics price target raised to $95 from $65 at Goldman Sachs
PremiumThe Fly
Protagonist Therapeutics price target raised to $95 from $65 at Goldman Sachs
14d ago
PTGX
Protagonist Therapeutics price target raised to $100 from $86 at Wedbush
PremiumThe Fly
Protagonist Therapeutics price target raised to $100 from $86 at Wedbush
15d ago
TAK
PTGX
Takeda, Protagonist announce FDA acceptance of rusfertide new drug application
PremiumThe Fly
Takeda, Protagonist announce FDA acceptance of rusfertide new drug application
15d ago
TAK
PTGX
Protagonist Therapeutics price target raised to $95 from $93 at JPMorgan
PremiumThe Fly
Protagonist Therapeutics price target raised to $95 from $93 at JPMorgan
18d ago
PTGX
Regulatory Turbulence: FDA Disruptions and U.S. Government Shutdown Threaten Protagonist Therapeutics’ Development Timelines
PremiumCompany AnnouncementsRegulatory Turbulence: FDA Disruptions and U.S. Government Shutdown Threaten Protagonist Therapeutics’ Development Timelines
18d ago
PTGX
Protagonist Therapeutics price target raised to $100 from $90 at TD Cowen
Premium
The Fly
Protagonist Therapeutics price target raised to $100 from $90 at TD Cowen
19d ago
PTGX
Protagonist Therapeutics: Near-Term Cash Windfall and Strategic Partnerships Underpin Buy-Rated, Self-Funded Growth Story
Premium
Ratings
Protagonist Therapeutics: Near-Term Cash Windfall and Strategic Partnerships Underpin Buy-Rated, Self-Funded Growth Story
19d ago
PTGX
Protagonist Therapeutics price target raised to $112 from $102 at Citizens
PremiumThe Fly
Protagonist Therapeutics price target raised to $112 from $102 at Citizens
19d ago
PTGX
Protagonist Therapeutics price target raised to $113 from $108 at Barclays
PremiumThe Fly
Protagonist Therapeutics price target raised to $113 from $108 at Barclays
19d ago
PTGX
Protagonist Therapeutics: Late-Stage Pipeline Strength and Rusfertide Economics Drive Buy Rating and $100 Price Target
PremiumRatings
Protagonist Therapeutics: Late-Stage Pipeline Strength and Rusfertide Economics Drive Buy Rating and $100 Price Target
19d ago
PTGX
Protagonist Therapeutics price target raised to $117 from $80 at H.C. Wainwright
PremiumThe Fly
Protagonist Therapeutics price target raised to $117 from $80 at H.C. Wainwright
2M ago
PTGX
Protagonist Therapeutics: Advancing Multi-Asset Inflammation and Obesity Pipeline with Strong Cash Runway Supports Buy Rating
PremiumRatingsProtagonist Therapeutics: Advancing Multi-Asset Inflammation and Obesity Pipeline with Strong Cash Runway Supports Buy Rating
2M ago
PTGX
Protagonist Therapeutics Highlights Diversified Pipeline and Partnerships
Premium
Company Announcements
Protagonist Therapeutics Highlights Diversified Pipeline and Partnerships
2M ago
8K
PTGX
Advancing, De-Risked Pipeline and Near-Term Regulatory Catalysts Underpin Protagonist Therapeutics Buy Rating
Premium
Ratings
Advancing, De-Risked Pipeline and Near-Term Regulatory Catalysts Underpin Protagonist Therapeutics Buy Rating
2M ago
PTGX
Protagonist Therapeutics price target raised to $110 from $88 at Truist
PremiumThe Fly
Protagonist Therapeutics price target raised to $110 from $88 at Truist
2M ago
PTGX
Takeda, Protagonist Therapeutics submit rusfertide new drug application to FDA
PremiumThe Fly
Takeda, Protagonist Therapeutics submit rusfertide new drug application to FDA
2M ago
TAK
PTGX
Protagonist Therapeutics price target raised to $108 from $88 at Barclays
PremiumThe Fly
Protagonist Therapeutics price target raised to $108 from $88 at Barclays
3M ago
PTGX
Promising Clinical Data and Strategic Collaborations Drive Buy Rating for Protagonist Therapeutics
PremiumRatings
Promising Clinical Data and Strategic Collaborations Drive Buy Rating for Protagonist Therapeutics
3M ago
PTGX
Protagonist Therapeutics price target raised to $115 from $98 at Citi
PremiumThe FlyProtagonist Therapeutics price target raised to $115 from $98 at Citi
3M ago
PTGX
Protagonist, Takeda present longer-term data at ASH 2025 on rusfertide
Premium
The Fly
Protagonist, Takeda present longer-term data at ASH 2025 on rusfertide
3M ago
TAK
PTGX
Protagonist Therapeutics price target raised to $65 from $47 at Goldman Sachs
Premium
The Fly
Protagonist Therapeutics price target raised to $65 from $47 at Goldman Sachs
4M ago
PTGX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >